US Stock MarketDetailed Quotes
XENE Xenon Pharmaceuticals
- 41.150
- +1.350+3.39%
Close Nov 22 16:00 ET
- 43.000
- +1.850+4.50%
Post 20:01 ET
3.14BMarket Cap-14644P/E (TTM)
41.620High39.665Low335.42KVolume40.060Open39.800Pre Close13.76MTurnover0.48%Turnover RatioLossP/E (Static)76.24MShares50.99052wk High3.93P/B2.90BFloat Cap29.00052wk Low--Dividend TTM70.47MShs Float50.990Historical High--Div YieldTTM4.91%Amplitude2.100Historical Low41.009Avg Price1Lot Size
Xenon Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -6.38%-51.15M | 1.63%-32.68M | -25.48%-43.18M | -47.65%-145.33M | 9.52%-29.62M | -58.14%-48.08M | -96.95%-33.22M | -86.73%-34.41M | -41.62%-98.43M | -58.05%-32.73M |
| Net income from continuing operations | -29.57%-62.79M | -22.05%-57.92M | -14.87%-47.93M | -45.48%-182.39M | -19.65%-44.74M | -30.45%-48.46M | -52.32%-47.46M | -112.14%-41.73M | -58.94%-125.37M | -46.28%-37.4M |
| Operating gains losses | 121.26%64K | 125.50%114K | 180.00%4K | -123.45%-640K | 115.59%113K | -110.16%-301K | -170.50%-447K | 96.48%-5K | 734.56%2.73M | -484.68%-725K |
| Depreciation and amortization | -61.42%669K | 9.47%659K | 69.21%599K | 118.04%3.54M | 65.24%851K | 384.36%1.73M | 60.53%602K | -5.85%354K | 79.25%1.62M | 90.74%515K |
| Deferred tax | -106.41%-322K | -48.66%-333K | 39.93%403K | -563.64%-292K | -4,100.00%-200K | 23.15%-156K | -115.38%-224K | 11.63%288K | -175.86%-44K | -98.55%5K |
| Change In working capital | 72.38%-911K | 46.39%10.09M | -320.56%-5.65M | 933.58%5.64M | -148.97%-522K | -37.13%-3.3M | 0.04%6.89M | 141.17%2.56M | 74.46%-676K | 5.54%1.07M |
| -Change in receivables | -153.55%-83K | -151.16%-22K | -83.19%38K | -92.60%130K | -119.41%-294K | 2,114.29%155K | -88.97%43K | 245.81%226K | 482.79%1.76M | 214.97%1.52M |
| -Change in prepaid assets | 1,100.00%960K | -24.45%958K | -122.96%-673K | 115.00%1.57M | 60.89%-2.53M | 97.85%-96K | 78.34%1.27M | 1,177.57%2.93M | -591.83%-10.5M | -529.70%-6.47M |
| -Change in payables and accrued expense | 46.74%-1.79M | 64.00%9.15M | -744.78%-5.02M | -51.24%3.93M | -61.76%2.3M | -263.36%-3.36M | -3.58%5.58M | 89.76%-594K | 171.36%8.06M | 60.14%6.02M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -6.38%-51.15M | 1.63%-32.68M | -25.48%-43.18M | -47.65%-145.33M | 9.52%-29.62M | -58.14%-48.08M | -96.95%-33.22M | -86.73%-34.41M | -41.62%-98.43M | -58.05%-32.73M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -96.33%1.98M | 296.81%110.72M | -199.10%-46.2M | 60.42%-117.17M | -1,613.11%-245.58M | 123.02%53.88M | 2,018.60%27.9M | 195.36%46.62M | -19.95%-296M | 93.35%-14.34M |
| Net PPE purchase and sale | 50.83%-590K | 29.02%-1.51M | 91.48%-188K | -94.09%-5.62M | 95.55%-78K | -210.88%-1.2M | -292.10%-2.13M | -940.57%-2.21M | -41.17%-2.89M | -240.86%-1.75M |
| Net investment purchase and sale | -95.33%2.57M | 273.67%112.23M | -194.24%-46.01M | 61.94%-111.55M | -1,851.02%-245.5M | 123.57%55.08M | 1,513.92%30.04M | 200.31%48.83M | -19.77%-293.11M | 94.15%-12.58M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -96.33%1.98M | 296.81%110.72M | -199.10%-46.2M | 60.42%-117.17M | -1,613.11%-245.58M | 123.02%53.88M | 2,018.60%27.9M | 195.36%46.62M | -19.95%-296M | 93.35%-14.34M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 26.95%353.52M | 5,400,133.33%324.01M | -37.78%278.47M | -100.00%6K | ||||||
| Net common stock issuance | ---- | ---- | ---- | 27.26%353.49M | --323.98M | ---- | ---- | ---- | -37.90%277.77M | --0 |
| Proceeds from stock option exercised by employees | ---- | ---- | ---- | -95.04%35K | ---- | ---- | ---- | ---- | 171.15%705K | -60.00%6K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | ---- | ---- | ---- | 26.95%353.52M | 5,400,133.33%324.01M | ---- | ---- | ---- | -37.78%278.47M | -100.00%6K |
| Net cash flow | ||||||||||
| Beginning cash position | 111.82%136.73M | -15.27%58.9M | 159.67%148.64M | -67.42%57.24M | -3.78%99.57M | -82.55%64.55M | -40.35%69.51M | -67.42%57.24M | 290.34%175.69M | 17.86%103.49M |
| Current changes in cash | -239.24%-49.17M | 1,567.19%78.04M | -831.96%-89.38M | 178.50%91.03M | 203.74%48.82M | 113.39%35.31M | -102.09%-5.32M | 120.54%12.21M | -188.34%-115.96M | -153.59%-47.06M |
| Effect of exchange rate changes | 118.75%54K | -156.27%-202K | -722.03%-367K | 115.14%376K | -69.78%246K | 89.33%-288K | 140.20%359K | -79.86%59K | -319.59%-2.48M | 1,079.71%814K |
| End cash Position | -12.00%87.62M | 111.82%136.73M | -15.27%58.9M | 159.67%148.64M | 159.67%148.64M | -3.78%99.57M | -82.55%64.55M | -40.35%69.51M | -67.42%57.24M | -67.42%57.24M |
| Free cash flow | -4.99%-51.74M | 3.28%-34.19M | -18.43%-43.37M | -48.97%-150.94M | 13.89%-29.69M | -60.06%-49.28M | -103.04%-35.35M | -96.44%-36.62M | -41.61%-101.32M | -62.48%-34.48M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data